Once from the drug manufacturers copay assistance program and then again from our chronic disease patients. To be clear, this policy allows the insurance company to double dip and get paid twice.
UHC’s new Copay Accumulator Policy could financially ruin many of the most vulnerable patients. This policy will affect many of those who receive infusion therapy, like patients with cancer, arthritis, AIDS, and multiple sclerosis. Beginning on January 1, 2021, UHC will take their copay accumulator policy a step further and also pocket the assistance of patients who receive infusions in their doctor’s office. Now they want to take it beyond the pharmacy counter and into the doctor’s office. The goal of assistance is to help lessen the deductible burden and rising out of pocket costs for patients.īeginning in 2018, insurers like United Healthcare (UHC) and Blue Cross Blue Shield, started crediting this assistance to the insurance company, often leaving patients stranded at the pharmacy counter unable to pick up their medication once their assistance award ran out. A copay assistance program is where a drug company arranges for financial assistance to credit the patient’s account directly at the pharmacy counter. These drugs often have copay assistance programs in place to help offset costs to patients. What is a Copay Accumulator?Ĭopay accumulator programs target the most costly specialty drugs. The following post is from Julie Baak, the Practice Manager for the Arthritis Center in Saint Louis, Missouri and a fierce patient advocate.
0 kommentar(er)
